Environmental

ARDX shows above-peer R&D intensity, which supports pipeline sustainability, but the metric also implies a higher resource footprint than more capital-efficient biotech peers.

Its gross profit profile is structurally strong versus many peers, yet environmental relevance remains limited because the business model is less manufacturing-intensive than large-scale industrial healthcare peers.

The available data do not indicate material emissions or waste advantages, so the environmental score is held to a moderate level relative to peers with clearer operational disclosure.

Negative net debt suggests limited balance-sheet pressure on environmental spending, but this is a secondary factor versus peers with stronger disclosed environmental management systems.

Social

ARDX’s elevated R&D spend supports patient-focused innovation, which is a positive social signal versus peers with weaker commitment to therapeutic development.

The company’s high gross margin profile can help sustain investment in clinical and medical engagement, improving social resilience relative to more financially constrained peers.

Stock-based compensation remains meaningful, which can align employee incentives, but it also dilutes the social score versus peers with tighter compensation discipline.

No major labor, product safety, or access controversies are evident in the provided data, leaving ARDX positioned modestly above average on social factors.

Governance

Stock-based compensation at 12.1% of revenue is relatively high, which can weaken governance quality versus peers with tighter dilution control.

Debt-to-equity of 1.72 indicates moderate leverage, and while not excessive for biotech, it leaves governance more exposed than peers with cleaner capital structures.

Negative net debt to EBITDA suggests liquidity support, but governance remains only moderate because the data do not show superior capital allocation discipline versus peers.

R&D intensity is consistent with a development-stage model, yet the absence of broader disclosure on board oversight and controls limits a stronger governance assessment.

Overall Score

ARDX screens as moderately positioned versus peers overall, with stronger social characteristics offset by only average governance and limited environmental differentiation.

Score Driver: High R&D Intensity Supports Social Positioning, But Elevated Stock-Based Compensation Prevents A Stronger Overall ESG Relative Score.